A Florida federal judge has ruled in favor of a comparatively small compounding pharmacy over Novo Nordisk, the massive manufacturer of Ozempic and Wegovy. The case centered on allegations that the pharmacy violated state law by selling compounded versions of semaglutide, the active ingredient in these drugs.
U.S. District Judge William F. Jung granted summary judgment to the pharmacy, determining that Novo Nordisk’s claims were moot, preempted by federal law, and otherwise nonviable.
Subscribe to continue reading
- Unlimited access to our content and archive
- Exclusive access to our newsletter
- Join the Conversation! Exclusive access to article comments.
